Basic Information
Entacapone Orion
Regulatory Information
EMEA/H/C/002440
Authorised
August 18, 2011
June 23, 2011
11
September 24, 2024
Company Information
Finland
Orionintie 1 FI-02200 Espoo
ORION CORPORATION
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Entacapone Orion. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Entacapone Orion.